The Latest Breaking News from Kenvue

Johnson & Johnson stock (JNJ) recently spun off its consumer Kenvue business, which trades separately under the symbol KVUE. However, JNJ stock has dipped and now looks like good value.

Johnson & Johnson is signing off on a new logo, more than 130 years after creating the old one

What you need to know… The S&P 500 Index ($SPX ) (SPY ) today is up +0.11%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.46%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.65%. Stocks this morning are mixed. An increase in M&A...

Kenvue, spun off from Johnson & Johnson in May, generated $15 billion in sales last year, enough to put it at rank 275 on 2022's Fortune 500 list.

The IPO market is expected to thrive in the second half of 2023. Deals are getting larger and less volatile.

Johnson & Johnson rips off Band-Aid and spits out Listerine in a bid to boost margins.

The medical industry, which thrived during the pandemic years, is envisioned to remain buoyed despite the economic headwinds, thanks to the inelastic demand the sector faces. Against this backdrop, we think the strong fundamentals of Johnson and Johnson (JNJ) make it a wise portfolio addition. Read on….

Rising anxieties owing to the likelihood of an impending recession have weighed heavily on the stock market. Given the uncertainties are not likely to ease anytime soon, quality stocks Johnson & Johnson (JNJ) and Pfizer (PFE) might be wise portfolio additions to help you keep money in your pockets. Read…